Kalvista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Transcript

Why It Matters

The upside from Fanapt and new product launches offsets declining legacy sales, positioning Vanda for revenue growth but underscoring cash‑flow pressure and execution risk.

Key Takeaways

• Fanapt sales rose 26% YoY to $29.6M
• Hetlioz sales fell 24% YoY to $15.9M
• Dysanti received FDA approval for bipolar and schizophrenia
• Nirius launched direct‑to‑consumer with 65% cash‑pay discount
• 2026 revenue guidance lifted to $240‑$290M

Pulse Analysis

Vanda Pharmaceuticals is navigating a transitional phase where legacy antipsychotic revenues are eroding while newer assets gain traction. Fanapt’s 26% year‑over‑year growth, fueled by expanded bipolar indications and an enlarged sales force, lifted total prescriptions by 32% and new‑to‑brand starts by 76%. This commercial momentum partially offsets the 24% decline in Hetlioz sales, which continues to feel the impact of generic competition. The company’s ability to sustain Fanapt’s growth will be critical as it seeks to diversify revenue streams.

The launch of Nirius marks a strategic shift toward a direct‑to‑consumer model, offering the motion‑induced vomiting therapy at a 65% cash‑pay discount. By bypassing traditional pharmacy channels, Vanda aims to capture price‑sensitive patients and accelerate market penetration. Simultaneously, Dysanti’s FDA approval expands the portfolio into bipolar I disorder and schizophrenia, with data exclusivity through 2031 and patent protection until 2044, providing a longer‑term revenue buffer. These product introductions are complemented by late‑stage pipeline candidates targeting major depressive disorder, GLP‑1‑associated nausea, and social anxiety, positioning the firm for future growth.

Financially, Vanda raised its 2026 revenue guidance to $240‑$290 million, reflecting confidence in Nirius and Dysanti contributions, yet the quarter’s $48.6 million net loss and a $61.5 million cash drawdown highlight heightened spending. With $202.3 million in cash and marketable securities, the company must balance continued commercial investment against cash‑burn concerns. Investors will watch SG&A trends, the uptake of Nirius’s cash‑pay model, and upcoming Phase 3 readouts, which together will determine whether Vanda can translate its expanded product suite into sustainable profitability.